Pfizer’s high-stakes bet on antibody-drug conjugates (ADCs) has hit a speed bump. | Pfizer announced Monday that sigvotatug ...
GlobalData on MSN
Pfizer reports topline data from SigVie-002 study for NSCLC
The trial enrolled 703 participants who had previously received one or more lines of systemic therapy.
Zacks Investment Research on MSN
Pfizer's mixed phase III data for Sigvotatug Vedotin in NSCLC
Pfizer PFE has announced top-line data from a late-stage study which evaluated its investigational antibody-drug conjugate ...
Lyme disease is the most common tick-borne infectious disease in the United States. There is no vaccine to protect against it in humans. Biopharmaceutical company Pfizer and Valne ...
Results from multiple Phase 2b dose finding studies for berobenatide (PF’3944) highlight a potential first-in-class monthly GLP-1 receptor agonist (GLP-1 RA) peptide, and support the planned Phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results